95 related articles for article (PubMed ID: 34614040)
1. [Molecular classification of pancreatic cancer].
Tímár J
Magy Onkol; 2021 Oct; 65(3):201-205. PubMed ID: 34614040
[TBL] [Abstract][Full Text] [Related]
2. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
[TBL] [Abstract][Full Text] [Related]
3. Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS.
Duan YF; Li DF; Liu YH; Mei P; Qin YX; Li LF; Lin QX; Li ZJ
Hepatobiliary Pancreat Dis Int; 2013 Apr; 12(2):204-9. PubMed ID: 23558076
[TBL] [Abstract][Full Text] [Related]
4. Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities.
Lee MS; Pant S
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-13. PubMed ID: 33929876
[TBL] [Abstract][Full Text] [Related]
5. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
6. Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.
Brauswetter D; Gurbi B; Varga A; Várkondi E; Schwab R; Bánhegyi G; Fábián O; Kéri G; Vályi-Nagy I; Peták I
PLoS One; 2017; 12(9):e0185687. PubMed ID: 28957417
[TBL] [Abstract][Full Text] [Related]
7. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
8. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients.
Cheng H; Luo G; Jin K; Fan Z; Huang Q; Gong Y; Xu J; Yu X; Liu C
Cancer Med; 2020 Mar; 9(6):2153-2159. PubMed ID: 32017404
[TBL] [Abstract][Full Text] [Related]
9. Genomic profile concordance between pancreatic cyst fluid and neoplastic tissue.
Laquière AE; Lagarde A; Napoléon B; Bourdariat R; Atkinson A; Donatelli G; Pol B; Lecomte L; Curel L; Urena-Campos R; Helbert T; Valantin V; Mithieux F; Buono JP; Grandval P; Olschwang S
World J Gastroenterol; 2019 Sep; 25(36):5530-5542. PubMed ID: 31576098
[TBL] [Abstract][Full Text] [Related]
10. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
[TBL] [Abstract][Full Text] [Related]
11. Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer.
Brychta N; Krahn T; von Ahsen O
Clin Chem; 2016 Nov; 62(11):1482-1491. PubMed ID: 27591291
[TBL] [Abstract][Full Text] [Related]
12. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
13. [KRAS mutation assay on EUS-FNA specimens from pacients with pancreatic mass].
Bunganič B; Hálková T; Benešová L; Belšánová B; Laclav M; Hrůzová M; Traboulsi E; Frič P; Suchánek Š; Minárik M; Zavoral M
Cas Lek Cesk; 2016; 155(1):48-51. PubMed ID: 26898792
[TBL] [Abstract][Full Text] [Related]
14. Multiple KRAS mutations in pancreatic adenocarcinoma: molecular features of neoplastic clones indicate the selection of divergent populations of tumor cells.
Visani M; de Biase D; Baccarini P; Fabbri C; Polifemo AM; Zanini N; Pession A; Tallini G
Int J Surg Pathol; 2013 Dec; 21(6):546-52. PubMed ID: 23426962
[TBL] [Abstract][Full Text] [Related]
15. KRAS in pancreatic cancer.
Agarwal A; Saif MW
JOP; 2014 Jul; 15(4):303-5. PubMed ID: 25076326
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic value of important driver gene mutations in patients with radical resection of pancreatic cancer].
Shen J; Gao SZ; Wang H; Shi XH; Li B; Pan YQ; Shen S; Shao Z; Guo SW; Jin G
Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):840-847. PubMed ID: 31694133
[No Abstract] [Full Text] [Related]
17. Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer.
Yang S; Che SP; Kurywchak P; Tavormina JL; Gansmo LB; Correa de Sampaio P; Tachezy M; Bockhorn M; Gebauer F; Haltom AR; Melo SA; LeBleu VS; Kalluri R
Cancer Biol Ther; 2017 Mar; 18(3):158-165. PubMed ID: 28121262
[TBL] [Abstract][Full Text] [Related]
18. Multi-omics analysis based on integrated genomics, epigenomics and transcriptomics in pancreatic cancer.
Kong L; Liu P; Zheng M; Xue B; Liang K; Tan X
Epigenomics; 2020 Mar; 12(6):507-524. PubMed ID: 32048534
[No Abstract] [Full Text] [Related]
19. KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review.
Zhou L; Baba Y; Kitano Y; Miyake K; Zhang X; Yamamura K; Kosumi K; Kaida T; Arima K; Taki K; Higashi T; Imai K; Hashimoto D; Yamashita Y; Chikamoto A; Beppu T; Tan X; Baba H
Med Oncol; 2016 Apr; 33(4):32. PubMed ID: 26927447
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
